<DOC>
	<DOC>NCT00004647</DOC>
	<brief_summary>OBJECTIVES: I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.</brief_summary>
	<brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution. The first group receives oral mexiletine 3 times a day for 6 weeks. The dose is increased after the first week if there are no side effects. The second group receives a placebo. Patients cross to the alternate treatment after a 1-week washout.</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Paresthesia</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>Patients with painful diabetic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>diabetic neuropathy</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>neurologic and psychiatric disorders</keyword>
	<keyword>pain</keyword>
	<keyword>rare disease</keyword>
</DOC>